Abstract:Ruthenium(II) polypyridyl complexes have drawn growing attention due to their photophysical properties and anticancer activity. Herein we report four ruthenium(II) polypyridyl complexes [(N^N)2RuII(L)]2+ (1-4, L = 4-anilinoquinazoline derivatives, N^N = bidentate ligands with bis-nitrogen donors) as multi-functional anticancer agents. The epidermal growth factor receptor (EGFR) is overexpressed in a broad range of cancer cells and related to many kinds of malignance. EGFR inhibitors, such as gefitinib and erlotinib, have been approved as clinical anticancer drugs. The EGFR-inhibiting 4-anilinoquinazoline ligands greatly enhanced the in vitro anticancer activity of these ruthenium(II) polypyridyl complexes against a series of human cancer cell lines compared to [Ru(bpy)2(phen)], but interestingly, these complexes were actually not potent EGFR inhibitors. Further mechanism studies revealed that upon irradiation with visible light, complexes 3 and 4 generated a high level of singlet oxygen (1O2), and their in vitro anticancer activities against human non-small-cell lung (A549), cervical (HeLa) and squamous (A431) cancer cells were significantly improved. Specifically, complex 3 displayed potent phototoxicity upon irradiation with blue light, of which the photo-toxicity indexes (PIs) against HeLa and A431 cells were 11 and 8.3, respectively. These complexes exhibited strong fluorescence emission at ca. 600 nm upon excitation at about 450 nm. A subcellular distribution study by fluorescence microscopy imaging and secondary ion mass spectrometry imaging (ToF-SIMS) demonstrated that complex 3 mainly localized at the cytoplasm and complex 4 mainly localized in the nuclei of cells. Competitive binding with ctDNA showed that complex 4 was more favorable to bind to the DNA minor groove than complex 3. These differences support that complex 3 possibly exerts its anticancer activities majorly by photo-induced 1O2 generation and complex 4 by binding to DNA.

Luminescent ruthenium(II) polypyridyl complexes acted as radiosensitizer for pancreatic cancer by enhancing radiation-induced DNA damage.

Ruthenium(II) Complexes with 2-Phenylimidazo[4,5-f][1,10]phenanthroline Derivatives that Strongly Combat Cisplatin-Resistant Tumor Cells

Ruthenium(II) Polypyridyl Complexes with Visible Light-Enhanced Anticancer Activity and Multimodal Cell Imaging.

Biocompatible Ruthenium Polypyridyl Complexes As Efficient Radiosensitizers.

Rational Design of Ruthenium Complexes Containing 2,6‐bis(benzimidazolyl)pyridine Derivatives with Radiosensitization Activity by Enhancing P53 Activation

Photoexpulsion of Surface-Grafted Ruthenium Complexes and Subsequent Release of Cytotoxic Cargos to Cancer Cells from Mesoporous Silica Nanoparticles.

Mixed-ligand ruthenium polypyridyl complexes as apoptosis inducers in cancer cells, the cellular translocation and the important role of ROS-mediated signaling.

Half‐sandwich Ruthenium (II) Complexes with Triphenylamine Modified Dipyridine Skeleton and Application in Biology/luminescence Imaging

Ruthenium(II) Polypyridyl Complexes: Cellular Uptake, Cell Image and Apoptosis of HeLa Cancer Cells Induced by Double Targets

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Increasing the cytotoxicity of Ru(II) polypyridyl complexes by tuning the electron donating ability of 1,10-phenanthroline ligands

Ruthenium(II) Polypyridyl Complexes As Mitochondria-Targeted Two-Photon Photodynamic Anticancer Agents

Trinuclear ruthenium(II) polypyridyl complexes: Evaluation as photosensitizers for enhanced cervical cancer treatment

A Novel Ruthenium(ii)-Polypyridyl Complex Inhibits Cell Proliferation and Induces Cell Apoptosis by Impairing DNA Damage Repair.

Ruthenium Complex-Modified Carbon Nanodots For Lysosome-Targeted One- And Two-Photon Imaging And Photodynamic Therapy

Ruthenium Complexes as Promising Candidates against Lung Cancer

New ruthenium polypyridyl complexes functionalized with fluorine atom or furan: Synthesis, DNA-binding, cytotoxicity and antitumor mechanism studies

Organometallic ruthenium and iridium phosphorus complexes: Synthesis, cellular imaging, organelle targeting and anticancer applications: Organometallic Complexes Synthesis and Applications

A Selenium-Containing Ruthenium Complex As a Cancer Radiosensitizer, Rational Design and the Important Role of ROS-mediated Signalling

Highly Potent Half- Sandwich Iridium and Ruthenium Complexes As Lysosome- Targeted Imaging and Anticancer Agents

Ruthenium Complexes Containing 2,6-Bis(benzimidazolyl)pyridine Derivatives Induce Cancer Cell Apoptosis by Triggering Dna Damage-Mediated P53 Phosphorylation